Sinovac Biotech, Ltd. (NASDAQ:SVA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.

ILLEGAL ACTIVITY WARNING: “Sinovac Biotech, Ltd. (SVA) Upgraded to Buy at BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/sinovac-biotech-ltd-sva-upgraded-to-buy-at-bidaskclub/1674788.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its holdings in Sinovac Biotech by 10.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,679,490 shares of the biopharmaceutical company’s stock valued at $9,623,000 after buying an additional 154,690 shares in the last quarter. Eqis Capital Management Inc. grew its holdings in shares of Sinovac Biotech by 0.6% during the 2nd quarter. Eqis Capital Management Inc. now owns 156,779 shares of the biopharmaceutical company’s stock worth $1,058,000 after purchasing an additional 983 shares in the last quarter. Morgan Stanley grew its holdings in shares of Sinovac Biotech by 86,309.9% during the 1st quarter. Morgan Stanley now owns 2,721,912 shares of the biopharmaceutical company’s stock worth $15,597,000 after purchasing an additional 2,718,762 shares in the last quarter. GLG Partners LP grew its holdings in shares of Sinovac Biotech by 144.8% during the 2nd quarter. GLG Partners LP now owns 282,611 shares of the biopharmaceutical company’s stock worth $1,908,000 after purchasing an additional 167,165 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Sinovac Biotech by 18.5% during the 2nd quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 7,711 shares in the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.